The management of type 2 diabetes mellitus (T2DM) is becoming increasingly complex.
Sodium–glucose cotransporter type 2 inhibitors (SGLT2is) are the newest antidiabetic …

Empaglifolzin, canagliflozin, and dapagliflozin are SGLT2 (sodium-glucose linked
transporter type 2) inhibitors for treatment of type 2 diabetes mellitus that also reduce blood …

Background and aims Glucose lowering agents that reduce the risk of major adverse
cardiovascular events (MACE) would be considered a major advance. The reduction of …

Objective: Sodium glucose cotransporter 2 inhibitors (SGLT2-is) are antidiabetic drugs that
improve glycemic control by limiting urinary glucose reuptake in the proximal tubule. SGLT2 …

The effects of the selective sodium-glucose cotransporter 2 (SGLT2) inhibitor empagliflozin
in low dose on cardiac function were investigated in normoglycemic rats. Cardiac …

Following myocardial ischemic injury, the most effective clinical intervention is timely
restoration of blood perfusion to ischemic but viable myocardium to reduce irreversible …

Background: The incidence of cardiovascular disease (CVD) is increased in patients with
diabetic kidney disease (DKD). Summary: Aortic stiffness is a well-accepted biomarker for …

Aim To evaluate the impact of sodium glucose cotransporter 2 inhibitors (SGLT-2i) on risk of
heart failure hospitalization in patients with type 2 diabetes. Methods We searched the …

Aim To determine the reasons for hospitalizations in the CANagliflozin cardioVascular
Assessment Study (CANVAS) programme and the effects of the sodium‐glucose co …

Cardiovascular disease (CVD) represents a major burden in patients with type 2 diabetes
(T2DM), with at least a twofold increase in myocardial infarction and ischemic stroke, and a …